Fluoropyrimidine Metabolism and Mechanism of Action.- 5-Fluoro-2?-Deoxyuridine: Role of Schedule in its Therapeutic Efficacy.- Comparison of Continuous Infusions and Bolus Injections of 5- Fluorouracil with or without Leucovorin: Implications for Inhibition of Thymidylate Synthase.- Critical Questions for the Future Direction of FU/LV.- Cellular Interactions Between the Natural and Unnatural Isomers of 5-Formyltetrahydrofolate.- Leucovorin as a Prodrug.- Clinical Use of Leucovorin: Intracellular Metabolism.- Some Considerations Concerning the Dose and Schedule of 5FU and Leucovorin: Toxicities of Two Dose Schedules from the Intergroup Colon Adjuvant Trial (INT-0089).- Effects of 5-Fluorouracil on mRNA.- Genetic Variation in Thymidylate Synthase Confers Resistance to 5-Fluorodeoxyuridine.- Experience with 5FU + L-Leucovorin.- 5-Fluorouracil Combined with the Pure [6S]-Stereoisomer of Folinic Acid in High Doses for Treatment of Patients with Advanced Colorectal Carcinoma: A Phase I-II Study of Two Consecutive Regimens.- 5-Fluorouracil Modulation in Colorectal Carcinoma: Experience of German Investigators.- An Overview of Adjuvant Treatment of Colon Cancer.- Dose-Dependent Inhibition of Aspartate Carbamoyltransferase in Peripheral Blood Mononuclear Cells in Patients Receiving N-Phosphonacetyl)-L-Aspartate.- Alternative Approaches to Modulation of Fluoropyrimidines.- Increasing the Efficacy of 5-Fluorouracil with Interferons: Preclinical, Clinical, and Pharmacokinetic Studies.- Enchanced Cytotoxicity of 5-Fluorouracil Combined with [6RS]-Leucovorin and Recombinant Human Interferon-?2a in Colon Carcinoma Cells.- Regulation of Thymidylate Synthase in Human Colon Cancer Cells Treated with 5-Fluorouracil and Interferon-Gamma.- Biochemical Modulation of 5-Fluorouracil by PALA: Mechanism of Action.- Implications of Chronobiology for 5-Fluorouracil (5-FU) Efficacy.- Update on Metabolic Modulation as a Therapeutic Approach for Adult Carcinomas.- Fluorouracil and Leucovorin in Advanced Breast Cancer.- Fluorouracil Modulation in Head and Neck Cancer.- Biomodulation in Head and Neck Carcinomas: Therapeutic Approaches in Europe.- Rationale for the Combination Therapy of 5FU and CDDP.- Biochemical Modulation of Fluoropyrimidines: The "Giscad" Studies.- New Drugs.- Clinical Experience with UFT in Japan.- Clinical Studies of the Modulation of Ftorafur.- The Role of the Reduced-Folate Carrier and Metabolism to Intracellular Polyglutamates for the Activity of ICI D1694.- The History of the Development and Clinical Use of CB 3717 and ICI D1694.- New Sites of Intervention in the Development of New Drugs in Solid Tumors.- P53: A Determinant of the Cell Cycle Response to DNA Damage.- Therapeutic Implications of Molecular Genetics.- Concluding Remarks.- Summary.- Abbreviations.- Author Index.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
Etat : New. In. N° de réf. du vendeur ria9780306445927_new
Quantité disponible : Plus de 20 disponibles
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Etat : As New. Unread book in perfect condition. N° de réf. du vendeur 45210962
Quantité disponible : Plus de 20 disponibles
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Buch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Fluoropyrimidine Metabolism and Mechanism of Action.- 5-Fluoro-2 -Deoxyuridine: Role of Schedule in its Therapeutic Efficacy.- Comparison of Continuous Infusions and Bolus Injections of 5- Fluorouracil with or without Leucovorin: Implications for Inhibition of Thymidylate Synthase.- Critical Questions for the Future Direction of FU/LV.- Cellular Interactions Between the Natural and Unnatural Isomers of 5-Formyltetrahydrofolate.- Leucovorin as a Prodrug.- Clinical Use of Leucovorin: Intracellular Metabolism.- Some Considerations Concerning the Dose and Schedule of 5FU and Leucovorin: Toxicities of Two Dose Schedules from the Intergroup Colon Adjuvant Trial (INT-0089).- Effects of 5-Fluorouracil on mRNA.- Genetic Variation in Thymidylate Synthase Confers Resistance to 5-Fluorodeoxyuridine.- Experience with 5FU + L-Leucovorin.- 5-Fluorouracil Combined with the Pure [6S]-Stereoisomer of Folinic Acid in High Doses for Treatment of Patients with Advanced Colorectal Carcinoma: A Phase I-II Study of Two Consecutive Regimens.- 5-Fluorouracil Modulation in Colorectal Carcinoma: Experience of German Investigators.- An Overview of Adjuvant Treatment of Colon Cancer.- Dose-Dependent Inhibition of Aspartate Carbamoyltransferase in Peripheral Blood Mononuclear Cells in Patients Receiving N-Phosphonacetyl)-L-Aspartate.- Alternative Approaches to Modulation of Fluoropyrimidines.- Increasing the Efficacy of 5-Fluorouracil with Interferons: Preclinical, Clinical, and Pharmacokinetic Studies.- Enchanced Cytotoxicity of 5-Fluorouracil Combined with [6RS]-Leucovorin and Recombinant Human Interferon- 2a in Colon Carcinoma Cells.- Regulation of Thymidylate Synthase in Human Colon Cancer Cells Treated with 5-Fluorouracil and Interferon-Gamma.- Biochemical Modulation of 5-Fluorouracil by PALA: Mechanism of Action.- Implications of Chronobiology for 5-Fluorouracil (5-FU) Efficacy.- Update on Metabolic Modulation as a Therapeutic Approach for Adult Carcinomas.- Fluorouracil and Leucovorin in Advanced Breast Cancer.- Fluorouracil Modulation in Head and Neck Cancer.- Biomodulation in Head and Neck Carcinomas: Therapeutic Approaches in Europe.- Rationale for the Combination Therapy of 5FU and CDDP.- Biochemical Modulation of Fluoropyrimidines: The 'Giscad' Studies.- New Drugs.- Clinical Experience with UFT in Japan.- Clinical Studies of the Modulation of Ftorafur.- The Role of the Reduced-Folate Carrier and Metabolism to Intracellular Polyglutamates for the Activity of ICI D1694.- The History of the Development and Clinical Use of CB 3717 and ICI D1694.- New Sites of Intervention in the Development of New Drugs in Solid Tumors.- P53: A Determinant of the Cell Cycle Response to DNA Damage.- Therapeutic Implications of Molecular Genetics.- Concluding Remarks.- Summary.- Abbreviations.- Author Index. 336 pp. Englisch. N° de réf. du vendeur 9780306445927
Quantité disponible : 2 disponible(s)
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
Etat : New. N° de réf. du vendeur 45210962-n
Quantité disponible : Plus de 20 disponibles
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Etat : New. N° de réf. du vendeur 45210962-n
Quantité disponible : Plus de 20 disponibles
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
Etat : As New. Unread book in perfect condition. N° de réf. du vendeur 45210962
Quantité disponible : Plus de 20 disponibles
Vendeur : THE SAINT BOOKSTORE, Southport, Royaume-Uni
Hardback. Etat : New. This item is printed on demand. New copy - Usually dispatched within 5-9 working days. N° de réf. du vendeur C9780306445927
Quantité disponible : Plus de 20 disponibles
Vendeur : moluna, Greven, Allemagne
Gebunden. Etat : New. KlappentextProceedings of an international symposium held in Buffalo, N.Y., September 1992. With the major diseases of focus being advanced and adjuvant colorectal cancer, head and neck cancer, and breast cancers, the volume is divided i. N° de réf. du vendeur 897688022
Quantité disponible : Plus de 20 disponibles
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Hardcover. Etat : Brand New. 336 pages. 10.25x7.00x1.00 inches. In Stock. N° de réf. du vendeur x-0306445921
Quantité disponible : 2 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Buch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - Fluoropyrimidine Metabolism and Mechanism of Action.- 5-Fluoro-2 -Deoxyuridine: Role of Schedule in its Therapeutic Efficacy.- Comparison of Continuous Infusions and Bolus Injections of 5- Fluorouracil with or without Leucovorin: Implications for Inhibition of Thymidylate Synthase.- Critical Questions for the Future Direction of FU/LV.- Cellular Interactions Between the Natural and Unnatural Isomers of 5-Formyltetrahydrofolate.- Leucovorin as a Prodrug.- Clinical Use of Leucovorin: Intracellular Metabolism.- Some Considerations Concerning the Dose and Schedule of 5FU and Leucovorin: Toxicities of Two Dose Schedules from the Intergroup Colon Adjuvant Trial (INT-0089).- Effects of 5-Fluorouracil on mRNA.- Genetic Variation in Thymidylate Synthase Confers Resistance to 5-Fluorodeoxyuridine.- Experience with 5FU + L-Leucovorin.- 5-Fluorouracil Combined with the Pure [6S]-Stereoisomer of Folinic Acid in High Doses for Treatment of Patients with Advanced Colorectal Carcinoma: A Phase I-II Study of Two Consecutive Regimens.- 5-Fluorouracil Modulation in Colorectal Carcinoma: Experience of German Investigators.- An Overview of Adjuvant Treatment of Colon Cancer.- Dose-Dependent Inhibition of Aspartate Carbamoyltransferase in Peripheral Blood Mononuclear Cells in Patients Receiving N-Phosphonacetyl)-L-Aspartate.- Alternative Approaches to Modulation of Fluoropyrimidines.- Increasing the Efficacy of 5-Fluorouracil with Interferons: Preclinical, Clinical, and Pharmacokinetic Studies.- Enchanced Cytotoxicity of 5-Fluorouracil Combined with [6RS]-Leucovorin and Recombinant Human Interferon- 2a in Colon Carcinoma Cells.- Regulation of Thymidylate Synthase in Human Colon Cancer Cells Treated with 5-Fluorouracil and Interferon-Gamma.- Biochemical Modulation of 5-Fluorouracil by PALA: Mechanism of Action.- Implications of Chronobiology for 5-Fluorouracil (5-FU) Efficacy.- Update on Metabolic Modulation as a Therapeutic Approach for Adult Carcinomas.- Fluorouracil and Leucovorin in Advanced Breast Cancer.- Fluorouracil Modulation in Head and Neck Cancer.- Biomodulation in Head and Neck Carcinomas: Therapeutic Approaches in Europe.- Rationale for the Combination Therapy of 5FU and CDDP.- Biochemical Modulation of Fluoropyrimidines: The 'Giscad' Studies.- New Drugs.- Clinical Experience with UFT in Japan.- Clinical Studies of the Modulation of Ftorafur.- The Role of the Reduced-Folate Carrier and Metabolism to Intracellular Polyglutamates for the Activity of ICI D1694.- The History of the Development and Clinical Use of CB 3717 and ICI D1694.- New Sites of Intervention in the Development of New Drugs in Solid Tumors.- P53: A Determinant of the Cell Cycle Response to DNA Damage.- Therapeutic Implications of Molecular Genetics.- Concluding Remarks.- Summary.- Abbreviations.- Author Index. N° de réf. du vendeur 9780306445927
Quantité disponible : 2 disponible(s)